Manage episode 332992632 series 3009792
Heart attack caused by rupture of unstable plaque in the coronary arteries is the number one cause of death worldwide.
Melbourne-based medtech company Nirtek, is using laser technology discovered at the Baker Heart and Diabetes Institute, to develop the first intra-coronary guidewire device for the detection of unstable plaque to prevent heart attacks and save lives. Nirtek’s device has been awarded funding through MTPConnect’s Targeted Translation Research Accelerator program for Diabetes & Cardiovascular Disease, made possible by the Medical Research Future Fund.
MTPConnect hosts Caroline Duell and Lauren Kelly, Senior Director of the TTRA Program are joined by Nirtek’s CEO Matthew Hoskin, who shares the challenges of their medtech journey as the company prepares for a capital raise and works towards creating a prototype for clinical trials. Matthew also explains the value of the support provided by the Medical Device Partnering Program (MDPP), a TTRA venture partner, and MDPP’s Olivia White joins the discussion.